You are here

ACH-2928

5 Biotech Stocks That Could Soar On New Hepatitis C Drugs

Seeking Alpha

Sat, 04/21/12 - 12:17 pm

Abbott Laboratories

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Yahoo/Globe NewsWire

Sat, 04/21/12 - 12:05 pm

Achillion: A Compelling 'Buy' Candidate Now

Motley Fool

Mon, 04/16/12 - 11:51 am